Sodium- and chloride-dependent glycine transporter 1

Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
FDA, Research, IRON, Glycine, Erythropoiesis, Food, EPP, PV, Sodium- and chloride-dependent glycine transporter 1, G&A, AURORA, Iron, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ruxolitinib, Light, Porphyria, Inflammation, Poster, Sunlight, Society, ASH, Development, Photosensitivity, Hematology, Quality of life, Phase 10, Anemia, PPIX, Safety, MF, XLP, Pain, Patient, Administration, Polycythemia, Rare-earth element, Pharmaceutical industry, Vaccine, Disc

Third Quarter 2023 Financial Results:

Key Points: 
  • Third Quarter 2023 Financial Results:
    Cash Position: Cash and cash equivalents were $370.5 million as of September 30, 2023, which are expected to fund our operational plans well into 2026.
  • Research and Development Expenses: R&D expenses were $14.4 million for the quarter ended September 30, 2023, as compared to $7.9 million for the quarter ended September 30, 2022.
  • General and Administrative Expenses: G&A expenses were $4.5 million for the quarter ended September 30, 2023, as compared to $2.6 million for the same period in 2022.
  • Net Loss: Net loss was $14.1 million for the quarter ended September 30, 2023, as compared to $16.2 million for the third quarter of 2022.

Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, August 11, 2023
Sodium- and chloride-dependent glycine transporter 1, Ruxolitinib, Chronic kidney disease, European Hematology Association, EPP, AURORA, G&A, Porphyria, Inflammation, MF, Dialysis, Congress, IRON, Development, Erythropoiesis, Glycine, Patient, Administration, Anemia, EHA, Mab, XLP, Research, Polycythemia, Technology transfer, Safety, Pharmaceutical industry, Nursing, Cryptocurrency, Vaccine, Disc

Disc plans to initiate a Phase 1 study in healthy volunteers during the second half of 2023.

Key Points: 
  • Disc plans to initiate a Phase 1 study in healthy volunteers during the second half of 2023.
  • Second Quarter 2023 Financial Results:
    Cash Position: Cash and cash equivalents were $377.6 million as of June 30, 2023, which are expected to fund our operational plans well into 2026.
  • Research and Development Expenses: R&D expenses were $12.1 million for the quarter ended June 30, 2023, as compared to $7.7 million for the quarter ended June 30, 2022.
  • Net Loss: Net loss was $15.9 million for the quarter ended June 30, 2023, as compared to $9.6 million for the second quarter of 2022.

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)

Retrieved on: 
Thursday, July 27, 2023
Diamond, Sodium- and chloride-dependent glycine transporter 1, DBA, Head, EPP, Principal investigator, National Heart, Lung, and Blood Institute, CRADA, Research, Diamond–Blackfan anemia, Lung, Bangladesh Technical Education Board, Development, NHLBI, IRON, Cooperative research and development agreement, Patient, Erythropoietic protoporphyria, EHA, NIH, Disease, Pharmaceutical industry

Bitopertin is an investigational, orally administered glycine transporter 1 (GlyT1) inhibitor designed to modulate heme biosynthesis.

Key Points: 
  • Bitopertin is an investigational, orally administered glycine transporter 1 (GlyT1) inhibitor designed to modulate heme biosynthesis.
  • “The start of this trial represents another step toward demonstrating the potential of bitopertin to address a wide range of hematologic conditions.” said Will Savage, M.D., Ph.D., Chief Medical Officer of Disc.
  • The study includes planned dose escalation within each participant to continually assess for hematologic response.
  • Upon completion of the main treatment period, patients may continue on extended treatment within the trial.

Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA

Retrieved on: 
Saturday, June 10, 2023
PPIX, Sodium- and chloride-dependent glycine transporter 1, LSE, Disc, Biotechnology, Quality of life, Congress, Patient, Erythropoietic protoporphyria, EHA, XLP, Bitopertin, Photosensitivity, Safety, Pharmaceutical industry, EPP

The initial trial data from the BEACON study demonstrated consistent decreases in protoporphyrin IX (the disease-causing metabolite in EPP), significant increases in reported sunlight tolerance and improvements in measures of patient quality of life.

Key Points: 
  • The initial trial data from the BEACON study demonstrated consistent decreases in protoporphyrin IX (the disease-causing metabolite in EPP), significant increases in reported sunlight tolerance and improvements in measures of patient quality of life.
  • The BEACON trial is a randomised, open-label, parallel-arm trial enrolling up to 22 patients with EPP or XLP at trial sites in Australia.
  • Robert Lyne, CEO of Arix Bioscience, said: “We are very encouraged by the positive data from the BEACON trial.
  • We look forward to supporting Disc Medicine as they continue to advance the BEACON study through clinical development.

Disc Presents Positive Initial Data from Phase 2 BEACON Trial of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress

Retrieved on: 
Friday, June 9, 2023
EPIQ, Sodium- and chloride-dependent glycine transporter 1, Protoporphyrin IX, European Hematology Association, Metallicity, Disc, Week, EPP, Bitopertin, Quality of life, First grade, Pain, Congress, Sunlight, IRON, Patient, Erythropoietic protoporphyria, EHA, XLP, Photosensitivity, Poster, Safety, Disease, Pharmaceutical industry, Medical device, Sewage treatment, PPIX

The initial trial data demonstrated consistent decreases in PPIX, significant increases in reported sunlight tolerance and improvements in measures of patient quality of life.

Key Points: 
  • The initial trial data demonstrated consistent decreases in PPIX, significant increases in reported sunlight tolerance and improvements in measures of patient quality of life.
  • “We’re delighted to share these initial, positive data from BEACON, which provide the first clinical evidence supporting our therapeutic hypothesis of bitopertin in EPP.
  • Due to batch processing of samples, the data cutoff for PPIX data was April 7, 2023.
  • Management will host a call to review the presented data on Friday, June 9th at 7:30 am ET.

Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 15, 2023
Diamond, Sodium- and chloride-dependent glycine transporter 1, Interim, Diamond–Blackfan anemia, Ruxolitinib, Chronic kidney disease, European Hematology Association, OrbiMed, AURORA, G&A, Porphyria, Inflammation, MF, Dialysis, Net, Congress, IRON, ATM, Erythropoiesis, Glycine, Development, Patient, Administration, Anemia, EHA, Mab, Research, FDA, Polycythemia, CKD, IND, NIH, TMPRSS6, Safety, Pharmaceutical industry, Generic drug, Vaccine, Cryptocurrency, Nursing, Disc, EPP, Greater China

Interim data will be presented at EHA Congress on June 9, 2023, with an accompanying management call at 7:30 am ET the same day.

Key Points: 
  • Interim data will be presented at EHA Congress on June 9, 2023, with an accompanying management call at 7:30 am ET the same day.
  • Announced a collaboration with NIH to study bitopertin in patients with Diamond-Blackfan Anemia in March 2023; the study is expected to initiate mid-year 2023.
  • First Quarter 2023 Financial Results:
    Cash Position: Cash and cash equivalents were $236.4 million as of March 31, 2023 compared to $194.6 million as of December 31, 2022.
  • Net Loss: The net loss was $22.8 million for the first quarter of 2023, as compared to $9.9 million for the first quarter of 2022.

Disc Medicine Reports Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Friday, March 31, 2023
Diamond, Janus, Sodium- and chloride-dependent glycine transporter 1, OrbiMed, Diamond–Blackfan anemia, Bitopertin, MF, Dialysis, Congress, Development, Patient, Mab, TMPRSS6, EPP, Porphyria, Thalassemia, Growth, FDA, Polycythemia, IND, NIH, Chronic kidney disease, AURORA, IRON, Erythropoiesis, Glycine, Administration, Erythropoietic protoporphyria, Anemia, XLP, Research, Therapy, Ruxolitinib, JAK, SAD, Inflammation, Orphan, Novo Holdings A/S, CKD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Generic drug, Pharmaceutical industry, Vaccine, Cryptocurrency, Greater China, Disc

In August 2022, Disc initiated BEACON, an open-label Phase 2 clinical study of bitopertin in patients with EPP and X-linked protoporphyria (XLP).

Key Points: 
  • In August 2022, Disc initiated BEACON, an open-label Phase 2 clinical study of bitopertin in patients with EPP and X-linked protoporphyria (XLP).
  • In October 2022, Disc initiated AURORA, a Phase 2 randomized, placebo-controlled clinical study of bitopertin in adults with EPP.
  • Disc completed a reverse merger with Gemini Therapeutics in December 2022, which resulted in Disc becoming publicly listed on NASDAQ, and raised approximately $90 million in operating capital.
  • Full Year 2022 Financial Results:
    Cash Position: Cash and cash equivalents were $194.6 million as of December 31, 2022 compared to $88.0 million as of December 31, 2021.

Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs

Retrieved on: 
Tuesday, February 14, 2023
Diamond, Erythropoiesis, AURORA, DBA, Diamond–Blackfan anemia, Erythropoietic protoporphyria, Science, IRON, CKD, Patient, Clinical trial, Polycythemia, Form, Inflammation, Anemia, Trial master file, Sodium- and chloride-dependent glycine transporter 1, OrbiMed, IND, S-3, Dialysis, FDA, Chronic kidney disease, HJV, EPP, Ruxolitinib, Doctor of Philosophy, Pharmaceutical industry, Security (finance), Disc

The financing was led by Bain Capital Life Sciences, who contributed $50 million, with participation from existing investors, Access Biotechnology and OrbiMed.

Key Points: 
  • The financing was led by Bain Capital Life Sciences, who contributed $50 million, with participation from existing investors, Access Biotechnology and OrbiMed.
  • The offering is expected to close on or about February 15, 2023, subject to customary closing conditions.
  • The shares of common stock and pre-funded warrants were offered pursuant to a shelf registration statement on Form S-3 (File No.
  • “We are delighted to welcome Bain Capital Life Sciences as an investor during a transformational time for Disc.

Disc Medicine Announces Completion of Merger with Gemini Therapeutics

Retrieved on: 
Thursday, December 29, 2022
Janus, Erythropoietic protoporphyria, Wilmer Cutler Pickering Hale and Dorr, Anemia, Ruxolitinib, Morgan Stanley, Sodium- and chloride-dependent glycine transporter 1, EPP, IRON, Bitopertin, Novo Holdings A/S, Patient, Degenerative disease, AURORA, Pharmaceutical industry, Disc, HJV

WATERTOWN, Mass., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (“Disc”), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that its previously-announced merger with Gemini Therapeutics, Inc. (“Gemini”) closed on December 29, 2022, following the approval of Gemini shareholders.

Key Points: 
  • WATERTOWN, Mass., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (“Disc”), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that its previously-announced merger with Gemini Therapeutics, Inc. (“Gemini”) closed on December 29, 2022, following the approval of Gemini shareholders.
  • Following the reverse stock split and closing of the merger, there will be approximately 17 million shares of the combined company’s common stock outstanding with prior Disc shareholders owning approximately 74% and prior Gemini shareholders owning 26%.
  • The Board of Directors of the combined company will be composed of nine members, including eight Disc board members and one board member from Gemini.
  • Morgan Stanley served as the lead financial advisor to Disc along with Wedbush PacGrow, and Goodwin Procter LLP served as Disc’s legal counsel.

Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics

Retrieved on: 
Wednesday, August 10, 2022
Diamond, Chronic kidney disease, Sickle cell disease, Sodium- and chloride-dependent glycine transporter 1, Hepcidin, Erythropoietic porphyria, Inflammation, Industry, DBA, AbbVie, Microdeletion syndrome, Genetic disorder, Cancer, Medicine, Diamond–Blackfan anemia, Hope, Patient, TMPRSS6, Biotechnology, Degenerative disease, Disc, Anemia, Polycythemia, Iron overload, Ruxolitinib, Hematologic disease, Thalassemia, Hereditary haemochromatosis, Pharmaceutical industry, HJV

Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders.

Key Points: 
  • Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders.
  • Disc is building a portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology.
  • Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease.
  • Disc has a clinical-stage development pipeline composed of investigational product candidates that affect heme biosynthesis and iron metabolism.